Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
1,14 USD | +1,79% | +3,64% | -8,06% |
09/05 | Transcript : Akebia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
09/05 | Akebia Therapeutics, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024 | CI |
Attività
Numero di dipendenti: 167
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100,0
%
| 292 | 100,0 % | 195 | 100,0 % | -33,46% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 292 | 100,0 % | 195 | 100,0 % | -33,46% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
John Butler
CEO | Chief Executive Officer | 59 | 01/07/13 |
Tracey Vetterick
ADM | Chief Administrative Officer | - | 01/04/22 |
Michel Dahan
COO | Chief Operating Officer | 45 | 01/01/13 |
Steven Burke
CTO | Chief Tech/Sci/R&D Officer | 63 | 17/06/19 |
Chief Tech/Sci/R&D Officer | - | - | |
Corporate Officer/Principal | - | - | |
Carolyn Rucci
LAW | General Counsel | - | 01/01/21 |
Meredith Bowman
HRO | Human Resources Officer | - | 01/05/22 |
Christian Barnes
PRN | Corporate Officer/Principal | - | - |
Nicholas Grund
PRN | Corporate Officer/Principal | 54 | 09/01 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Michael Rogers
BRD | Director/Board Member | 64 | 12/12/18 |
Adrian Adams
CHM | Chairman | 73 | 12/12/18 |
LeAnne Zumwalt
BRD | Director/Board Member | 65 | 16/02/21 |
John Butler
CEO | Chief Executive Officer | 59 | 01/07/13 |
Steven Gilman
BRD | Director/Board Member | 71 | 12/12/18 |
Ronald Frieson
BRD | Director/Board Member | 65 | 01/11/21 |
Cynthia Smith
BRD | Director/Board Member | 55 | 28/08/18 |
Myles Wolf
BRD | Director/Board Member | 53 | 06/04/20 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 209 596 378 | 192 384 386 ( 91,79 %) | 0 | 91,79 % |
Coordinate società
Akebia Therapeutics, Inc.
245 First Street Suite 1400
02142, Cambridge
+617 871 2098
http://www.akebia.comSettore
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-8,06% | 239 Mln | |
+15,55% | 121 Mrd | |
+12,66% | 107 Mrd | |
-2,53% | 24,82 Mrd | |
+1,14% | 22,48 Mrd | |
-9,35% | 18,32 Mrd | |
-42,28% | 16,33 Mrd | |
-18,92% | 15,31 Mrd | |
+6,19% | 14,08 Mrd | |
+28,83% | 11,74 Mrd |
- Borsa valori
- Azioni
- Azione AKBA
- Società Akebia Therapeutics, Inc.